fludarabine has been researched along with 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bengtzen, S; Lehmann, S; Merup, M; Mollgard, L; Nahi, H; Paul, C; Selivanova, G; Wiman, KG | 1 |
| Ali, D; Bengtzén, S; Deneberg, S; Jönsson-Videsäter, K; Lehmann, S; Nahi, H; Paul, C | 1 |
2 other study(ies) available for fludarabine and 2,2-bis(hydroxymethyl)-1-azabicyclo(2,2,2,)octan-3-one
| Article | Year |
|---|---|
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Synergism; Gene Deletion; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2004 |
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Aza Compounds; Base Sequence; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression; Genes, p53; Humans; Karyotyping; Leukemia, Myeloid, Acute; Male; Mutation; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF; Vidarabine | 2011 |